Can you provide information on ibogaine, including its uses, dosing, risks, contraindications, and required monitoring?

Ibogaine: Critical Safety Concerns Outweigh Unproven Benefits

Ibogaine cannot be recommended for clinical use due to severe cardiotoxicity, lack of proven efficacy, and multiple documented fatalities—the risks far exceed any potential benefits based on current evidence.

What is Ibogaine?

Ibogaine is a hallucinogenic alkaloid derived from the West African shrub Tabernanthe iboga, traditionally used in Bwiti tribal rituals. It has gained attention as a potential treatment for opioid use disorder (OUD) and other substance dependencies, but it is not FDA-approved and remains unlicensed in most countries including the United Kingdom 1.

Critical Safety Issues

Severe Cardiotoxicity

• QTc prolongation is universal and dangerous: In a controlled study of 14 OUD patients receiving 10 mg/kg ibogaine, the average maximum QTc prolongation was 95ms (range 29-146ms), with 50% of patients exceeding the critical threshold of 500ms 2
• Prolonged cardiac risk: In 6 of 14 patients, QTc remained above 450ms beyond 24 hours post-ingestion 2
• Life-threatening arrhythmias: Ibogaine causes polymorphic ventricular tachycardia (torsades de pointes) and cardiac arrest 3, 1
• Multiple fatalities documented: Deaths have occurred in patients with medical and substance use comorbidities 4, 1

Neurological Toxicity

• Severe ataxia is universal: All patients in controlled studies experienced severe transient cerebellar ataxia with inability to walk without support 2
• Neuropsychiatric effects: Coma, convulsions, stupor, anxiety, and psychomotor agitation requiring medication have been reported 5, 1

Other Adverse Effects

• Blood pressure alterations (mild to moderate) 5
• Common symptoms: drowsiness, nausea, anxiety, vomiting 5, 1
• Hypoxia 1

Dosing (Investigational Only—Not Recommended)

Note: The FDA label 6 you referenced appears to be for methocarbamol (Robaxin), NOT ibogaine. Ibogaine has no FDA-approved dosing.

In research settings only:

• Standard investigational dose: 10 mg/kg oral ibogaine hydrochloride as a single dose 7, 2
• Dose range in studies: 20-400 mg in escalating protocols 5
• One RCT used: 1800 mg single dose for cocaine dependence 4
• Toxic doses reported: 5-34 grams in case reports 1

Critical caveat: Ibogaine clearance is highly dependent on CYP2D6 genotype—clearance increases by 30.7 L/h for every point of CYP2D6 activity score, making dosing unpredictable without genetic testing 7.

Efficacy: Insufficient Evidence

What the Evidence Shows:

• Only ONE small double-blind RCT (n=20) showed reduced cocaine craving with 1800 mg ibogaine versus placebo over 24 weeks 4
• No double-blind RCT has demonstrated efficacy for OUD 8
• Most positive data comes from uncontrolled, open-label, or retrospective studies with high risk of bias, often conducted in non-clinical settings 8
• One RCT of noribogaine (ibogaine's metabolite) showed dose-dependent QTc prolongation but only non-significant reductions in withdrawal symptoms 4

The Bottom Line on Efficacy:

While observational data suggest ibogaine may alleviate OUD symptoms, these findings remain exploratory and are confounded by motivation and placebo effects 5, 8.

Contraindications & Required Monitoring

Absolute Requirements if Used (Research Only):

• Pre-screening mandatory: Rigorous cardiovascular screening including baseline ECG, electrolytes, cardiac history 5, 2
• CYP2D6 genotyping: Essential due to highly variable pharmacokinetics 7
• Continuous cardiac monitoring: For at least 24-48 hours, though QTc prolongation can persist beyond 24 hours 2
• Hospitalization required: 24-48 hours before dosing with continuous vital sign monitoring 5
• Emergency resuscitation capability: Must be immediately available 2

High-Risk Populations to Exclude:

• Any cardiac disease or QTc prolongation at baseline
• Electrolyte abnormalities
• Concurrent medications that prolong QTc
• Medical comorbidities
• Active polysubstance use 1

Clinical Context & Pitfalls

Common pitfall: Patients are obtaining ibogaine from online sources, dealers, or shamans in uncontrolled settings 1. All seven cases reported to UK poison control involved "recreational abuse" circumstances, with doses ranging wildly and sources unverified 1.

Critical distinction: Unlike classic psychedelics (psilocybin, LSD) which have demonstrated safety and efficacy in controlled trials, ibogaine has a narrow therapeutic margin and documented lethality 4, 8.

Microdosing data: Limited to one early study showing only slight improvements in selective attention with no clinically meaningful benefits 9.

Current Regulatory Status

• Not FDA-approved for any indication
• Unlicensed in the UK and most countries
• Schedule I in the United States (no accepted medical use)
• Used off-label in unregulated international clinics

Final Assessment

The current evidence is insufficient to support ibogaine's clinical use for any indication. 8 The documented cardiotoxicity—including universal QTc prolongation, risk of fatal arrhythmias, and multiple deaths—combined with lack of proven efficacy from rigorous trials, makes the risk-benefit ratio unacceptable. Patients inquiring about ibogaine should be counseled about these serious risks and directed toward evidence-based treatments for substance use disorders (methadone, buprenorphine, naltrexone) that have established safety profiles and proven mortality benefits.